Cinco preguntas críticas sobre la vacuna contra COVID-19 de Pfizer
La farmacéutica anunció que en una muestra pequeña se comprobó que podría prevenir la infección en nueve de cada 10 casos. Pero se necesitan más respuestas.
NIH ‘Very Concerned’ About Serious Side Effect in Coronavirus Vaccine Trial
The AstraZeneca trial is on hold in the U.S. as scientists try to unravel whether a rare neurological condition is linked to the vaccine. But regulators are frustrated by a lack of information from the drugmaker.
Los NIH, “muy preocupados” por efectos secundarios en ensayo de vacuna para COVID
La Administración de Alimentos y Medicamentos está evaluando la posibilidad de seguir a los reguladores británicos y reanudar el ensayo de la vacuna. Pero hay dudas.
LA Hospital Seeks Vaccine Trial Participants Among Its Own High-Risk Patients
Harbor-UCLA Medical Center serves patients who are especially vulnerable to the coronavirus: They are essential workers, have chronic diseases and are members of underrepresented racial and ethnic groups. When the safety-net hospital kicks off enrollment for its COVID-19 vaccine trial Wednesday, it will look to those patients to participate.
Trust, Fear and Solidarity Will Determine the Success of a COVID Vaccine
Polio terrified Americans, and in 1955, when Jonas Salk’s vaccine became available, they snapped it up like candy. Sixty-five years later, COVID is the latest dread virus, but many undercurrents could inhibit its acceptance.
Confianza, miedo y solidaridad marcarán el éxito de una vacuna contra COVID
Cuando una vacuna contra el coronavirus esté disponible, ¿la recibirán con una gran ovación, como la vacuna contra la polio, o con cierto letargo, como la vacuna contra el sarampión?
Public Health Experts Fear a Hasty FDA Signoff on Vaccine
The FDA must approve any coronavirus vaccine before it’s widely distributed, but political pressure could cloud the decision.
Analysis: Get Ready For The Vaccine — They’re Never Simple
Trials are an immense undertaking involving tens of thousands of participants. They’re likely to start this summer — but don’t expect quick results. And what’s a successful result, anyway?